Navigation Links
New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
Date:12/12/2007

Data Presented for the First Time on 50 mg/Day Dose for PRISTIQ for the

Treatment of Major Depressive Disorder

COLLEGEVILLE, Pa., Dec. 12 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announces that data from two Phase 3 clinical studies of PRISTIQ(TM) (desvenlafaxine), an investigational serotonin-norepinephrine reuptake inhibitor (SNRI), showed that adult patients who received a 50 mg/day dose of PRISTIQ for the treatment of major depressive disorder (MDD) experienced a statistically significant reduction in the symptoms of major depression compared to placebo. The two studies, which evaluated efficacy and safety of PRISTIQ for the treatment of MDD at fixed doses of 50 mg/day and 100 mg/day, will be presented today at a major medical meeting. This will be the first time an analysis of the 50 mg/day dose for PRISTIQ for the treatment of MDD is presented.

In both studies, discontinuation rates due to adverse events (AEs) for PRISTIQ 50 mg/day were similar to placebo. In the two studies, the rates of discontinuation due to AEs for placebo and PRISTIQ 100 mg/day were three percent and seven percent, respectively.

"These findings show that PRISTIQ has the potential to reduce symptoms of MDD at doses as low as 50 mg once daily," says Philip Ninan, M.D., Vice President, Neuroscience, Global Medical Affairs. "The response rates of patients in the 50 mg/day dose groups are similar to the rates seen at higher doses. We are also encouraged by the tolerability profile shown in the two studies presented at this meeting. Notably, subjects in the 50 mg/day dose groups were not titrated from a lower dose when initiating therapy."

Wyeth submitted in August 2007 the results
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
6. Phase III Trial Finds Pharmaxis Bronchitol Effective
7. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
8. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
9. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
10. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
11. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Rootstown, OH (PRWEB) January 22, 2015 Crystal ... announced today that it has received AOAC-PTM Certifications for the ... O111, O121, and O145; collectively referred to as STEC or ... at 1 colony forming unit (cfu) per 325 g of ...
(Date:1/22/2015)... Selexis SA, a serial innovation company with proven ... for drug discovery to commercial manufacturing, announced today all ... Sequencing (NGS) data packages. The NGS analysis of ... the integrity of the gene, validation of the left ...
(Date:1/22/2015)...   GenoSpace , a precision medicine software company that has ... use of genomic, imaging and other biomedical data in research ... Munson , CEO of Aspera, an IBM Company, to its ... http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased to welcome ...
(Date:12/24/2014)... 24, 2014  Vermillion, Inc. (Nasdaq:   VRML), a ... today that the Company closed its previously announced ... Jack W. Schuler , Birchview Fund LLC ... million, before offering expenses.  The proceeds will be ...
Breaking Biology Technology:Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2GenoSpace Expands Board with Appointment of Michelle Munson 2Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... Vasogen Inc.,(NASDAQ: VSGN ; TSX:VAS) today reported the results ... 31, 2008. All dollar amounts referenced,herein are in Canadian ... our cash and cash equivalents totaled $9.8 million,compared with ... loss for the third quarter of 2008 was $2.6 ...
... in Composite Events When Using Routine ... FFR Guidance in Multi-Vessel Disease, WASHINGTON, ... the launch of the PrimeWire(TM) Pressure,Guidewire, and the s5-FFR Option ... in the U.S. The PrimeWire is Volcano,s newest pressure,guidewire, capable ...
... Pillar of Support for National Children,s Program, ... and Chief,Scientific Officer of Tishcon Corp and visionary ... of low income children in,America. In January 2000, ... Patel, and Vice President, Arun Chopra, initiated a,monthly ...
Cached Biology Technology:Vasogen Announces Third Quarter 2008 Results 2Vasogen Announces Third Quarter 2008 Results 3Vasogen Announces Third Quarter 2008 Results 4Vasogen Announces Third Quarter 2008 Results 5Vasogen Announces Third Quarter 2008 Results 6Vasogen Announces Third Quarter 2008 Results 7Vasogen Announces Third Quarter 2008 Results 8Vasogen Announces Third Quarter 2008 Results 9Vasogen Announces Third Quarter 2008 Results 10Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles 2Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles 3Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles 4Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles 5Tishcon Corp Reaches Donation Milestone Exceeds 1 Million Bottles of Multi-Vitamins for Nourish America 2Tishcon Corp Reaches Donation Milestone Exceeds 1 Million Bottles of Multi-Vitamins for Nourish America 3
(Date:1/22/2015)... /PRNewswire/ - Today, FindBiometrics, the leading source of biometrics industry news, ... website design. "When we launched FindBiometrics 12 years ... O,Neill , founder and CEO of FindBiometrics. "Now it,s maturing ... the key players on a very broad scale.  We are ...
(Date:1/22/2015)... Jan. 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD and ... reports on the recent success of the Wocket™ smart wallet at CES ... smart wallet was named as one of the "11 Hot Products at ... Products Launched At CES So Far" by Newseveryday.com and "The top 10 ...
(Date:1/22/2015)...   EyeLock, Inc. , a market leader of iris-based identity ... to the new role of Senior Vice President of ... of mobile platforms and wearable solutions for EyeLock,s technologies. Gerber ... the semiconductor industry to his role at EyeLock, with expertise ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
... great debate has raged over whether organic compounds and ... meteorite Allan Hills 84001 were processed by living creatures ... been under intense scrutiny ever since. Scientists at the ... fresh look at how material associated with carbonate globules ...
... concerns that hamper embryonic stem cell research, but they still ... with which adult stem cells differentiate into mature tissue the ... impossible for researchers to multiply them in the laboratory. And ... difficult to use them for treating disease. , Now, ...
... and Infectious Diseases (NIAID), part of the National Institutes ... anthrax toxin that worked well in small-scale animal tests. ... anthrax antitoxin is an important advance, not only for ... also because this technique could be used to design ...
Cached Biology News:Relic of life in that Martian meteorite? A fresh look 2Powerful technique for multiplying adult stem cells may aid therapies 2Powerful technique for multiplying adult stem cells may aid therapies 3Scientists design potent anthrax toxin inhibitor 2Scientists design potent anthrax toxin inhibitor 3
... PEP-152 is a 17 amino acid synthetic peptide whose sequence is ... (amino to carboxy terminus): C - N(217) - Q - ... - A - T - P - N - Y - ... may be used for neutralization and control experiments with the polyclonal ...
... a novel target for which no antibody exists? ... custom antibodies for a variety of pharmaceutical, biotech ... to put our technology and expertise in antibody ... to our patented RabMAb development technology , High ...
... The Rapid-Screen cDNA Library Panels were ... just three sets of PCRs to identify ... analysis is performed in a 96-well "Master ... from 5,000 clones. Having identified the positive ...
... The Rapid-Screen cDNA Library Panels were ... just three sets of PCRs to identify ... analysis is performed in a 96-well "Master ... from 5,000 clones. Having identified the positive ...
Biology Products: